Guardant360 enters a new breast cancer workflow built on testing every three months

Guardant Health, Inc. (NASDAQ: GH) has secured U.S. Food and Drug Administration approval for Guardant360 CDx as the companion diagnostic for AstraZeneca PLC’s newly approved Etcamah, or camizestrant, creating a potentially important new testing workflow in advanced breast cancer. The test identifies emerging ESR1 mutations in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic disease while they are still receiving an aromatase inhibitor plus a CDK4/6 inhibitor. Rather than waiting for clinical or radiographic disease progression, the FDA-authorized strategy allows treatment to switch after the mutation becomes detectable through circulating tumor DNA, and Guardant Health recommends repeat Guardant360 CDx testing every three months during therapy. In the pivotal SERENA-6 study, mutation-guided switching to camizestrant plus continued CDK4/6 inhibition reduced the risk of progression or death by 56% compared with continuing the aromatase inhibitor regimen.

The approval strengthens Guardant Health’s existing position in ESR1 testing rather than creating its first companion-diagnostic relationship in breast cancer. Guardant360 CDx had previously received FDA approvals associated with other targeted therapies for ESR1-mutated disease, but Etcamah introduces a different commercial dynamic because the test may be used repeatedly during first-line treatment to detect molecular resistance before conventional evidence of progression appears. For a diagnostics company, repeated longitudinal testing can be economically more attractive than a single test ordered only after treatment failure because each eligible patient can generate several potential testing events over time.

Why is ESR1 mutation monitoring becoming a treatment decision rather than just a laboratory result?

ESR1 mutations can develop under the selective pressure of aromatase-inhibitor therapy and allow estrogen-receptor signaling to continue despite treatment designed to suppress estrogen production. In conventional clinical practice, physicians may continue the initial endocrine regimen until imaging or symptoms show that disease has progressed, even though molecular resistance may have emerged earlier. SERENA-6 tested whether identifying the mutation through circulating tumor DNA before overt progression could create a window in which therapy is changed sooner.

The study randomized patients with newly detected ESR1 mutations to switch from an aromatase inhibitor to camizestrant while maintaining the same CDK4/6 inhibitor, or to continue the aromatase inhibitor plus CDK4/6 inhibitor. AstraZeneca reported a 56% reduction in the risk of disease progression or death in the camizestrant strategy, which formed the basis for accelerated FDA approval. The diagnostic therefore becomes inseparable from the treatment model because Etcamah eligibility in this setting depends on detecting the mutation with an FDA-authorized test before radiographic progression.

Why could testing every three months change Guardant360 CDx economics?

A conventional companion diagnostic may be ordered once to determine whether a patient carries a targetable mutation. Guardant Health’s Etcamah workflow is different because a patient who is initially ESR1-negative can acquire the mutation during treatment, creating a rationale for serial monitoring. The company’s recommendation for testing every three months gives the liquid-biopsy platform a potentially recurring role throughout first-line therapy rather than only at diagnosis or progression.

That does not guarantee that every eligible U.S. patient will be tested at three-month intervals because physician behavior, payer policies, guideline adoption and real-world treatment patterns will determine actual frequency. It does, however, expand the addressable testing opportunity per patient if ctDNA surveillance becomes incorporated into routine metastatic breast cancer care. The commercial importance could become larger if similar molecular-monitoring strategies emerge for additional cancers and therapies, turning liquid biopsy from a snapshot diagnostic into a longitudinal disease-management tool.

How large is Guardant Health’s oncology testing platform already?

Guardant Health generated second-quarter 2026 revenue of $335 million, up 44% from $232.1 million a year earlier. Oncology revenue increased 38% to $219.1 million, while oncology test volume rose 63% to approximately 104,000 tests during the quarter. The company also generated $52.9 million of screening revenue and $60.9 million from biopharma and data activities, illustrating that its business now extends well beyond a single precision-oncology assay.

Management increased full-year revenue guidance to $1.34 billion to $1.36 billion, implying 36% to 38% growth, and now expects oncology volume to grow approximately 50% during 2026. Growth still carries substantial cost because Guardant Health reported a $120.1 million second-quarter net loss, $69.5 million of negative free cash flow and $1.2 billion of cash, cash equivalents and restricted cash. The Etcamah companion-diagnostic approval is therefore strategically valuable, but investors still need the company’s high test-volume growth to translate into stronger operating leverage over time.

Why does Guardant Health have an advantage in a crowded liquid-biopsy market?

Guardant360 is already embedded across oncology treatment decisions and has accumulated multiple FDA companion-diagnostic approvals. Each additional approved drug relationship gives oncologists another reason to order the same platform because a broad genomic assay can potentially inform several treatment decisions rather than testing for only one biomarker. The Etcamah approval extends that advantage by giving Guardant Health a role at an earlier point in resistance evolution, before conventional radiographic progression.

The competitive risk is that liquid biopsy has become one of the most contested areas in molecular diagnostics, with established laboratory companies and sequencing specialists building their own assays and evidence. Guardant Health must therefore defend its position through clinical validation, turnaround time, payer access and integrations with drug-development programs rather than relying on technical novelty alone. The repeated-monitoring concept could become a powerful moat if oncologists increasingly use Guardant360 to follow tumor evolution, but that assumption still requires real-world adoption.

Why did GH shares barely move on the latest FDA approval?

Guardant Health shares closed at $161.41 on September 4, up only 0.23% on the day. The stock had traded as high as $176.58 during the previous 52 weeks and remained close to the upper end of a $53.40 to $176.58 annual range, showing that investors had already awarded the company a substantial valuation rerating before the Etcamah companion-diagnostic decision. Over the five sessions from August 28 to September 4, the shares were essentially flat, moving from $161.50 to $161.41 despite significant day-to-day volatility.

That reaction reflects Guardant Health’s scale and broad catalyst base. A single companion-diagnostic approval is unlikely to transform near-term revenue for a business guiding toward more than $1.3 billion of annual sales, but the underlying treatment model could matter over a longer period if serial ctDNA testing becomes routine. The strategic question is no longer whether Guardant Health can win FDA approvals for individual biomarkers. It is whether liquid biopsy can become an ongoing monitoring layer in cancer care, creating repeat testing volumes that conventional tissue diagnostics cannot easily replicate.